文献速递造血干细胞移植与细胞治疗

异基因造血干细胞移植治疗严重难治性幼年特发性关节炎

Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis.
PubMed 文献 · Blood Adv · 2018-01-01

该研究纳入5个移植中心2007至2016年间接受异基因造血干细胞移植的16例难治性幼年特发性关节炎患者,其中11例为全身型、5例为类风湿因子阴性多关节型;所有患者接受基于氟达拉滨的减低毒性预处理联合阿仑单抗血清治疗。中位随访29个月时14例存活,全部患者关节炎显著改善、巨噬细胞活化综合征缓解,11例达到完全无药缓解。

要点

  • 16例难治性幼年特发性关节炎患者接受阿仑单抗联合减低毒性预处理异基因移植,中位随访29个月时14例存活。
  • 全部患者关节炎显著改善、巨噬细胞活化综合征缓解,11例在末次随访时达到完全无药缓解。
  • 3例发生II-IV级急性移植物抗宿主病,移植后病毒感染发生率高,可能与使用阿仑单抗有关。

核心结论

  • 采用阿仑单抗和减低毒性预处理的异基因造血干细胞移植是常规治疗难治和或合并巨噬细胞活化综合征的幼年特发性关节炎患者有前景的治疗选择。
  • 需要长期随访以确定移植后的疾病控制是否无限期持续。

研究设计与样本

  • 研究纳入5个移植中心2007年至2016年间治疗的16例患者,其中11例为全身型幼年特发性关节炎、5例为类风湿因子阴性多关节型幼年特发性关节炎。
  • 所有患者均对标准治疗难治、或发生继发性噬血细胞性淋巴组织细胞增生症/巨噬细胞活化综合征且对治疗反应不佳、或自体造血干细胞移植失败。
  • 所有患儿接受基于氟达拉滨的减低毒性预处理方案和阿仑单抗血清治疗。

主要发现

  • 16例患者中14例存活,中位随访29个月(范围2.8-96个月)。
  • 所有患者均实现血液学恢复。
  • 3例患者发生II-IV级急性移植物抗宿主病。
  • 移植后病毒感染发生率高,可能由于在已重度免疫抑制的患者中使用了阿仑单抗。
  • 所有患者移植后早期关节炎显著改善、巨噬细胞活化综合征缓解、生活质量改善;11例儿童在末次随访时达到完全无药缓解。

局限性

  • 需要长期随访以确定移植后的疾病控制是否无限期持续。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with juvenile idiopathic arthritis (JIA) can experience a severe disease course, with progressive destructive polyarthritis refractory to conventional therapy with disease-modifying antirheumatic drugs including biologics, as well as life-threatening complications including macrophage activation syndrome (MAS). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative immunomodulatory strategy for patients with such refractory disease. We treated 16 patients in 5 transplant centers between 2007 and 2016: 11 children with systemic JIA and 5 with rheumatoid factor-negative polyarticular JIA; all were either refractory to standard therapy, had developed secondary hemophagocytic lymphohistiocytosis/MAS poorly responsive to treatment, or had failed autologous HSCT. All children received reduced toxicity fludarabine-based conditioning regimens and serotherapy with alemtuzumab. Fourteen of 16 patients are alive with a median follow-up of 29 months (range, 2.8-96 months). All patients had hematological recovery. Three patients had grade II-IV acute graft-versus-host disease. The incidence of viral infections after HSCT was high, likely due to the use of alemtuzumab in already heavily immunosuppressed patients. All patients had significant improvement of arthritis, resolution of MAS, and improved quality of life early following allo-HSCT; most importantly, 11 children achieved complete drug-free remission at the last follow-up. Allo-HSCT using alemtuzumab and reduced toxicity conditioning is a promising therapeutic option for patients with JIA refractory to conventional therapy and/or complicated by MAS. Long-term follow-up is required to ascertain whether disease control following HSCT continues indefinitely.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. M F Silva J, Ladomenou F, Carpenter B, et al. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis. Blood Adv. 2018. PMID: 29618462. doi:10.1182/bloodadvances.2017014449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。